The Effect of Rosuvastatin on Anemia Indicators and Iron Metabolism Indicators in Peritoneal Dialysis Patients with Anemia
ZU Yanping
Abstract：Objective To explore the effects of rosuvastatin on anemia and iron metabolism indicators of patients with peritoneal dialysis(PD)complicated with renal anemia(RA).Methods 94 patients with PD combined with RA were randomly divided into the control group(47)and the rosuvastatin group(47).They were treated with erythropoietin injection and rosuvastatin capsules,respectively,for 12 weeks.We compared the differences in various indicators and therapeutic effects between the two groups before and after treatment,and conduct statistical analysis on adverse reactions.Results Compared with the control group,the total effective rate of treatment in the rosuvastatin group was higher(P＜0.05).After treatment,the levels of Hb,RBC,and Hct were higher in the rosuvastatin group compared to the control group(P＜0.05).After treatment,compared to the control group,the rosuvastatin group had lower levels of ferritin(P＜0.05)and higher levels of transferrin and TAST(P＜0.05).The incidence of adverse reactions in the rosuvastatin group was 6.38％,which was significantly lower compared to the control group's 21.28％(P＜0.05).Conclusion Rosuvastatin can effectively correct anemia indicators and improve iron metabolism of patients with PD complicated with RA,and its efficacy and safety are better than those of erythropoietin injection.
Keywords：peritoneal dialysisanemiarosastairon metabolism disorders
Publication Date：2024-02-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 156-159 )